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DESCRIPTION of CASE
A 
35-year-old man came to the ofﬁ  ce with right-sided 
facial swelling, which he had noted over the last 
two years. The swelling was worse in the mornings 
and decreased through the day; however there were no 
symptom-free days. He had not experienced fevers, chills, or 
changes in his vision. He had experienced multiple episodes 
of lower extremity cellulitis, left more frequent than right 
leg, beginning in childhood. Although most instances were 
treated with oral antibiotics, he required hospitalization for 
intravenous antibiotics at least four times. Previous evaluation 
had conﬁ  rmed lymphedema by radionucleotide clearance. 
In addition, he had symptoms of allergic rhinitis and two 
episodes of otitis media as an adult, but he had no history of 
pneumonia or other signiﬁ  cant respiratory or gastrointestinal 
infections.
On physical examination he had no evidence of wasting 
or malnutrition. He had normal tonsils and no cervical 
lymphadenopathy; there was mild right facial swelling with 
induration and trace erythema from the eye to mid-cheek. 
The right facial skin was slightly warmer than the left, but it 
was non-tender to palpation. Tympanic membranes and chest 
examination were normal. His legs were moderately swollen, 
left greater than right, with a “woody” or indurated texture 
to the left leg; there were no rashes or other skin lesions. He 
had no hepatosplenomegaly.
What Investigations Are Indicated in This Patient?
Frequent infections raise the possibility of immunodeﬁ  ciency. 
A targeted immunologic evaluation should be guided by the 
clinical symptoms as well as the relative frequency of known 
immunodeﬁ  ciencies. 
Immune defects in the humoral system are most common 
and screening can be performed with tests for serum 
immunoglobulin levels and titers of speciﬁ  c antibody. A 
suggestion of immunoglobulin deﬁ  ciency arises if there 
is a low total protein on standard chemistry panels, as the 
immunoglobulins make up a considerable portion of serum 
proteins. Clinical symptoms of immunoglobulin deﬁ  ciency 
include increased frequency or severity of sino-pulmonary 
and other bacterial infections. 
Cellular immune deﬁ  ciencies are suggested by 
opportunistic and viral infections. An initial step in the 
evaluation of these is a complete blood count (a low 
lymphocyte number can be missed if only total white cells 
are counted) followed by a lymphocyte panel enumerating 
CD4 and CD8 T cells as well as B cells and natural killer cells. 
It is important to obtain the lymphocyte evaluation with a 
standard complete blood count to allow for the calculation 
of absolute numbers of cells and not just percentages, since 
normal relative percentages may be preserved despite very 
low cell numbers. More subtle defects in T cell function 
may be investigated by examining lymphocyte proliferative 
responses to mitogens and soluble antigens. 
Other rarer immune function defects, such as neutropenia 
or neutrophil dysfunction (e.g., chronic granulomatous 
disease leading to recurrent skin or organ abscesses), 
complement defects (systemic bacterial infections or 
meningitis), and IL-12 and interferon gamma axis 
dysfunction (mycobacterial infections), are less likely in 
this adult patient without clinical history or infections 
characteristic of these conditions.
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The Learning Forum discusses an important clinical problem of relevance 
to a general medical audience.
Table 1. Causes of Hypogammaglobulinemia
Primary Causes Examples
T cell defects Severe combined immunodeﬁ  ciency; hyper-IgM 
syndrome
B cell defects X linked agammaglobulinemia; common variable 
immunodeﬁ  ciency
Secondary Causes Examples
Decreased production Malignancy; medications; infection (perinatally 
acquired HIV); starvation
Loss High catabolism (very rare); protein-losing 
enteropathy; drainage of ascites 
or chylothorax
doi:10.1371/journal.pmed.0030475.t001PLoS Medicine  |  www.plosmedicine.org 2213
Laboratory data included low serum immunoglobulin G 
(IgG) 268 mg/dl (694–1618) and immunoglobulin M (IgM) 
18 mg/dl (48–271,) but normal serum immunoglobulin A 
(IgA) 119 mg/dl. Electrolytes, kidney, and liver function tests 
were normal. Serum calcium was 7.8 mg/dl (normal 8.5–
10.4), total protein was 4.8 g/dl (normal 6.0–8.3), albumin 
was 2.9 g/dl (normal 3.7–5.1), and calculated globulin was 
1.9 g/dl (normal 2.2–4.2). The urinalysis was normal with no 
protein detected. Further studies revealed normal white blood 
cell count (7.8 × 103/µl), hemoglobin, hematocrit, platelet 
count, and normal numbers of neutrophils, monocytes, 
eosinophils, and basophils. He had reduced numbers of 
lymphocytes 0.5 × 103/µl (normal 1.0–4.5 × 103/µl), consisting 
of reduced T cells 293 (750–2500/cu mm), CD4 T cells 238 
(480–1700/ cu mm), and CD8 T cells 40 (180–1000/cu mm), 
an increased CD4/CD8 ratio 6.10 (1.00–3.00), slightly low 
numbers of natural killer cells, 90 (135–525/cu mm), and 
normal numbers of B cells 85 (75–375/cu mm).
What Is the Differential Diagnosis?
Decreased immunoglobulin levels can result from reduced 
production or increased loss (Table 1). Primary causes of 
hypogammaglobulinemia are the genetic B or T cell defects. 
Secondary causes of reduced immunoglobulin production 
can be malignancy (lymphoma, thymoma, leukemia, 
multiple myeloma), selected medications (carbazepine [1], 
oxcarbazepine [2], immunosuppressive agents [3], and 
others), or infections such as Epstein-Barr virus, perinatally 
acquired HIV, or starvation. Increased nonselective loss of 
immunoglobulin can occur in rare states of high catabolism 
or with protein loss through protein-losing enteropathy 
(Table 2), drainage of ascites, or chylothorax (lymph ﬂ  uid in 
the pleural space).
Lymphedema may predispose to recurrent cellulitis 
in affected limbs, however, given the signiﬁ  cant 
hypogammaglobulinemia found here, an intrinsic defect 
in the immune system leading to an inability to eliminate 
infections should be investigated.
What Additional Laboratory Data or Investigations 
Would Be Helpful in Making a Diagnosis in This Patient?
The ability to make speciﬁ  c antibody after vaccination 
challenge can assist in differentiating between decreased 
production and increased loss of immunoglobulins. 
Defects in speciﬁ  c IgG antibody production are 
characteristic of primary immune defects such as X-linked 
agammaglobulinemia, hyper-IgM syndrome(s), and 
common variable immunodeﬁ  ciency (CVID). Patients with 
hypogammaglobulinemia due to protein loss would be 
expected to respond normally to vaccinations in generating 
plasma B cells producing speciﬁ  c IgG antibody, though 
there may be lower serum immunoglobulin levels due to the 
general loss of proteins including IgG antibodies. 
This man was ﬁ  rst assumed to have a primary immune 
deﬁ  ciency such as CVID, a syndrome most often associated 
with sino-pulmonary infections. The diagnosis of CVID is 
made by documenting decreased serum IgG, and IgA and/or 
IgM and poor speciﬁ  c antibody production [4]. Signiﬁ  cant 
improvement in infections is expected when IgG is replaced 
by immunoglobulin therapy [5]. CVID was considered a likely 
diagnosis, since it is often made during the second or third 
decade of life, however it is usually associated with a history of 
recurrent upper respiratory infections [6], not noted here. 
doi:10.1371/journal.pmed.0030475.g001
Figure 1. Response to Oral Budesonide
Stool protein loss, as measured by alpha-1 antitrypsin, decreased with 
oral locally active rapidly metabolized steroids and increased when the 
steroids were stopped, suggesting a steroid responsive gastrointestinal 
inﬂ  ammation as the underlying cause of the protein loss (including loss 
of immunoglobulins).
Table 2. Causes of Protein-Losing Enteropathy
Mode of Action Causes
Inﬂ  ammatory Inﬂ  ammatory bowel disease
Gastrointestinal malignancy
Pseudomembranous colitis due to Clostridium difﬁ  cile
Cytomegalovirus enteritis
Erosive gastritis/multiple gastric ulcers
Non-steroidal anti-inﬂ  ammatory drug enteropathy
Post-chemotherapy
Immune dysregulation, polyendocrinopathy, 
enteropathy, and X-linked inheritance (IPEX)
Lymphatic obstruction Intestinal lymphangiectasia
Right-sided heart failure
Cirrhosis
Hepatic venous outﬂ  ow obstruction
Enteric-lymphatic ﬁ  stula
Mesenteric tuberculosis or sarcoidosis
Intestinal lymphoma
Chronic pancreatitis with pseudocysts
Crohn disease
Whipple disease
Congenital malformations of lymphatics
Increased permeability Celiac disease
Tropical sprue
Giant hypertrophic gastritis (Menetrier disease)
Lymphocytic gastritis
Secretory hypertrophic gastropathy
Amyloidosis
Infections
Rheumatic diseases
Allergic gastroenteropathy
Eosinophilic gastroenteritis
Collagenous colitis
Protein-losing gastroenteropathy should be considered in any patient with 
hypoproteinemia.
Adapted from http://www.uptodate.com.
doi:10.1371/journal.pmed.0030475.t002
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However, other genetic immune defects and secondary 
causes, such as drug-induced, malignancy-associated 
hypogammaglobulinemia, or immunoglobulin loss, must be 
excluded. X-linked agammaglobulinemia and hyper-IgM were 
considered improbable due to the patient’s age, mild clinical 
history, normal numbers of B cells, normal serum IgA, and 
normal tonsillar tissue. 
Speciﬁ  c IgG antibody titers to varicella, rubella, and tetanus 
were found to be in a range considered to be protective, 
though the patient lacked sufﬁ  cient antibody to measles, 
mumps, and 12 serotypes of pneumococci. After vaccination 
with measles, mumps, and rubella (MMR) and pneumococcal 
vaccine, he developed protective speciﬁ  c antibody titers 
to measles and mumps and nine out of 14 pneumococcal 
serotypes. The preserved speciﬁ  c antibody production in 
response to pneumococcal, measles, and mumps vaccination, 
with the protective titers of antibody to varicella, rubella, and 
tetanus demonstrated normal B cell function, and excluded 
CVID. 
How Did We Investigate the Possibility of a Protein-
Losing Enteropathy?
Normal B cell function, low albumin, and the intermittent 
history of signiﬁ  cant lymphedema suggested the 
possibility of protein loss as the explanation for the 
hypogammaglobulinemia [7]. Normal urinalysis and renal 
functions eliminated nephrotic loss, which would have 
been an extremely unusual etiology for this degree of 
hypogammaglobulinemia. 
To evaluate gastrointestinal protein loss, stool alpha-
1 antitrypsin was determined and found to be elevated 
at 625 mg/dl (normal <55 mg/dl). This result suggested 
the presence of a protein-losing enteropathy such as 
intestinal lymphangiectasia. Intestinal lymphangiectasia 
may also be associated with the loss of T cells through the 
lymphatic channels. Although we did not evaluate this in 
our patient, in general naïve T cells are preferentially lost 
over memory T cells due to their trafﬁ  cking patterns though 
the lymphatic system [8,9]. However, the remaining T 
cells are generally able to prevent opportunistic infections. 
Intestinal lymphangiectasia was thus consistent with the 
patient’s reduced numbers of T cells and low levels of serum 
immunoglobulins.
What Was the Original Diagnosis?
Based on the presence of excess alpha-1 antitrypsin 
in the stool, the patient was diagnosed with protein-
losing enteropathy. Conditions leading to protein-losing 
enteropathy can be congenital or acquired. Our patient 
has had symptoms suggestive of lymphatic dilatation since 
childhood and congenital lymphangiectasia was considered 
as a leading diagnosis. The most likely type of congenital 
lymphangiectasia would be hereditary lymphedema type 
I (Milroy disease) (Table 3). Hereditary lymphedema 
type I is the result of a defect in the FLT4 gene, encoding 
vascular endothelial growth factor receptor-3 [10]. This is an 
autosomal dominant mutation with variable penetrance and 
expression in affected members of a family. Although our 
patient has no known affected family members, relatively mild 
disease may have been overlooked. However, the degree of 
facial swelling our patient experienced is not generally seen 
in this condition. 
Targeted evaluation for secondary causes of intestinal 
lymphangiectasia was conducted. Cardiac history and 
echocardiography were unremarkable in our patient, 
excluding cardiac disease as a secondary cause of his protein-
losing enteropathy. Upper and lower endoscopies by his 
local gastroenterologist did not reveal any visible anomalies 
indicative of Crohn disease, ulcerative colitis, or other lesions, 
suggesting that our patient’s protein loss was likely due to 
either a diffuse process or one occurring in the non-visualized 
small bowel. 
How Is Lymphangiectasia Treated?
Treatment for intestinal lymphangiectasia includes treatment 
of the underlying pathology if a secondary cause is present 
(Table 4). Our patient’s history is not consistent with any 
of the secondary causes of protein-losing enteropathy and 
he has chronic lymphedema of the face and extremities as 
well. Congenital intestinal lymphangiectasia can be surgically 
resected if there is an isolated segment of affected bowel. 
Most often there is diffuse intestinal involvement precluding 
resection. Other modalities have been used, including 
an extremely low fat diet to reduce the lymph ﬂ  ow to the 
intestinal mucosa, dietary medium chain triglycerides, or 
medications including heparin and octreotide [11–14]. 
However, our patient’s normal intestinal biopsy (no dilated 
lymphatics characteristic of lymphangiectasia) suggested 
these treatments were unlikely to be effective.
What Was the Final Diagnosis?
Since his history and biopsy ﬁ  ndings were not consistent with 
congenital or acquired lymphangiectasia, an inﬂ  ammatory 
etiology was considered; thus a diagnostic trial of topical oral 
steroids (budesonide) was given. After several weeks of use, 
Table 3. Features of Milroy Disease or Hereditary Lymphedema 
Type I
Genetic Features (Defect 
in the FLT4 Gene)
Clinical Features
Encodes vascular endothelial growth 
factor receptor-3 (VEGF-3)
Congenital developmental abnormality
Autosomal dominant Usually presents before the age of one 
year
Variable penetrance and expression 
in affected members of a family
Usually bilateral
Affects boys more often than girls
doi:10.1371/journal.pmed.0030475.t003
Table 4. Features and Secondary Causes of Intestinal 
Lymphangiectasia [15–19]
Features Secondary Causes
Low serum albumin and globulin levels 
in the absence of renal and hepatic 
disease
Cardiac (constrictive pericarditis, 
right-sided cardiac lesions)
Peripheral edema Infections (Whipple disease)
Lymphopenia Inﬂ  ammation (Crohn Disease)
May have steatorrhea and diarrhea Neoplasm (lymphoma)
Other aspects of intestinal absorptive 
function are normal
Obstruction of lymphatics (sclerosing 
mesenteritis, retroperitonitis, 
postradiation ﬁ  brosis, amyloidosis)
doi:10.1371/journal.pmed.0030475.t004
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the patient experienced a signiﬁ  cant decrease in facial and 
extremity lymphedema. Laboratory evaluation also revealed 
a decrease in stool protein loss with decreased stool alpha-
1 antitrypsin levels (Figure 1) suggesting an inﬂ  ammatory 
component to his protein-losing enteropathy. Based upon the 
response to steroids, an inﬂ  ammatory gastrointestinal process 
was considered to be the underlying cause of his protein-
losing enteropathy and subsequent hypogammaglobulinemia, 
but no speciﬁ  c etiology was identiﬁ  ed.
With good speciﬁ  c antibody production to vaccination 
challenge and no history of serious infections, replacement 
immunoglobulin therapy with intravenous immunoglobulin 
is not indicated. Continued close surveillance and a low 
threshold for the use of antibiotics would be prudent as he is 
at higher risk of recurrent cellulitis due to his lymphedema. 
Conclusion
The differential diagnosis of hypogammaglobulinemia 
includes evaluation for both primary and secondary causes, 
since the treatment for these conditions is different. Protein-
losing conditions can lead to hypogammaglobulinemia and 
loss of T cells, but immune function is generally preserved 
and immunoglobulin replacement therapy is not usually 
required.  
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Learning Points
•  Hypogammaglobulinemia can result from primary or 
secondary causes.
•  Secondary causes of hypogammaglobulinemia should 
be sought before diagnosing a patient with primary 
hypogammaglobulinemia.
•  Protein-losing enteropathy is a cause of secondary 
hypogammaglobulinemia and is associated with a low 
albumin as well as nonspeciﬁ  c serum protein loss.
•  T cells can also be lost in protein-losing enteropathies.
•  Not all hypogammaglobulinemia requires intravenous 
immunoglobulin replacement.
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